Fayetteville Competitive Bodybuilder Rings Cancer-Free Bell After Clinical Trial, WRAL Says

Three years, five months and ten days after a stage 4 colon cancer diagnosis that her mother was told might require planning a funeral, Bianca Harvey rang the Sound of Hope bell at Duke Cancer Center, WRAL reported.

Harvey, a competitive bodybuilder from Fayetteville, walked out of the clinic surrounded by the medical team that managed her case through two clinical trials after surgery was ruled out. “One, two, three. Cancer free. I did it y’all. Now I’m going to ring the bell for y’all. Y’all ready? Here we go,” she said before striking the bell.

Her oncologist, Dr. Nicholas DeVito, a gastrointestinal cancer specialist at Duke Health, said the response Harvey achieved on her second trial represents the trajectory he wants for every patient. “I want this to be the norm. I want people to come in with stage four colon cancers and us to have answers for them. And not just say it’s chemotherapy forever,” DeVito said.

The case lands amid a documented rise in early-onset colorectal cancer. Harvey first shared her story in the 2025 WRAL documentary Diagnosis: Young, which examined why cancers historically associated with older adults are increasingly diagnosed in people under 50. At the time of filming, she was still in active treatment.

“Whenever we did that documentary, I remember saying to myself, ‘Dang, I’m the only one that still has cancer. Everybody else is cured.’ And now I get to, you know, this is the happy end of it. So everybody else gets to also see that too,” Harvey told WRAL.

Fayetteville mom rings cancer-free bell after 3-year battle with stage 4 colon cancer — WRAL

The diagnosis that upended a life built on fitness

Harvey was physically active and preparing for bodybuilding competitions when symptoms appeared. By the time imaging confirmed the disease, it had metastasized, removing surgery as an option. Her mother, Teresa Harvey, recalled the initial prognosis bluntly: “We were told that when we brought her in that they were really planning for a funeral. They didn’t think that she would make it.”

The treatment toll was severe. “She said, ‘Mom, I’m just so thin. I can’t even walk.’ I said, ‘That doesn’t matter because guess what? I’m on one side and your dad’s on the other side, so let’s go,'” Teresa Harvey recounted.

Two trials, one dramatic reversal

DeVito enrolled Harvey in a first clinical trial; after roughly a year, the disease progressed. A second investigational regimen produced what Teresa Harvey described as an “orange that just died from the inside out” — tumors shrinking until scans showed no visible evidence of cancer.

Harvey credited DeVito’s persistence. “He has fought for me from the very beginning. And when I didn’t think there was a way, Dr. DeVito already had the plan mapped out,” she said at the bell-ringing ceremony. “That’s his field, that’s his specialty. So I just believed in him. I believed in him and I believed in God.”

She acknowledged the fear that accompanies experimental therapy. “At first we were a little scared to try the trial treatments, but the trial treatments are actually the way to go,” she said, urging other patients to ask their doctors about research options.

A data point in a younger demographic

Harvey’s experience reflects a clinical shift. The documentary Diagnosis: Young highlighted that screening guidelines have moved the recommended starting age to 45, but many patients like Harvey — diagnosed in her 30s — fall outside even that window.

While Harvey’s outcome is celebrated, it remains an individual response to an experimental protocol, not yet a validated standard for stage 4 disease.

Duke Cancer Institute, founded in 1971 and designated a National Cancer Institute Comprehensive Cancer Center in 1973, became a single integrated entity in 2010 combining patient care, basic science and clinical research. In 2012 it opened the Duke Cancer Center, a seven-floor building devoted exclusively to cancer care, where more than 10,000 new patients are seen each year.

The institute helped pioneer the first outpatient bone marrow transplant program in 1992 and contributed to the development of Avastin, the first targeted therapy that shut off a tumor’s blood supply.

“I want this to be the norm,” DeVito said.